01951nas a2200337   4500000000100000008004100001653002900042653000900071653001900080653002400099653001600123653001700139653000900156653001500165653001100180653001100191653002400202653002100226653001000247653002500257653001200282653001000294653001500304100001300319245012400332856008000456300001000536490000700546520104600553022001401599       1995                            d10aSkin Diseases, Parasitic10aSkin10aonchocerciasis10aOnchocerca volvulus10aMiddle Aged10aMicrofilaria10aMale10aIvermectin10aHumans10aFemale10aDouble-Blind Method10aChild, Preschool10aChild10aAntiparasitic Agents10aAnimals10aAdult10aAdolescent1 aBurnham 00aIvermectin treatment of onchocercal skin lesions: observations from a placebo-controlled, double-blind trial in Malawi.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750961/pdf/tropmed-52-270.pdf  a270-60 v523 a<p>To determine effects of ivermectin on skin lesions of onchocerciasis, a placebo-controlled, double-blind trial was carried out in the Thyolo highlands of Malawi involving 70 persons over a 32-month period. Assessment was made using both a clinical numeric grading system and sequential photographs. Among both ivermectin and placebo recipients, there was a significant reduction in both the severity and extent of papular skin lesions. Persons with edematous or lichenified skin lesions of onchocerciasis who received ivermectin showed significantly more improvement than those receiving placebo. Twelve months after the placebo group received ivermectin, their skin lesions were similar to those of the ivermectin group. Changes were most evident for those persons with more severe skin disease in both the ivermectin and placebo groups. Annual ivermectin treatment for onchocercal skin lesions is probably inadequate, and treatment three or four times a year may be required, although the optimum regimen has not been established.</p>
  a0002-9637